<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312350</url>
  </required_header>
  <id_info>
    <org_study_id>2010-10-028</org_study_id>
    <nct_id>NCT01312350</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN)</brief_title>
  <official_title>Concurrent Chemoradiation Versus Induction Docetaxel, Cisplatin and 5-fluorouracil (TPF) Followed by Concomitant Chemoradiotherapy in Locally Advanced Hypopharyngeal and Base of Tongue Cancer: A Randomized Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators will examine whether 2-cycles of DFP chemotherapy before definitive
      concurrent chemoradiation therapy (CCRT) can improve progression-free survival in locally
      advanced (Stage III &amp; IVM0) hypopharyngeal and base of tongue carcinoma compared to
      definitive CCRT alone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether addition of neoadjuvant chemotherapy before definite CCRT increase progression-free survival(PFS) compared with CCRT only</measure>
    <time_frame>18 months after the enrollment of the last patients</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether addtion of neoaduvant chemotherapy increase complete response rate compared with CCRT only</measure>
    <time_frame>18 months after enrollemnt of last patients</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether addtion of neoaduvant chemotherapy increase organ preservation rate compared with CCRT only</measure>
    <time_frame>18 months after the enrollment of the last patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine whether addition of neoadjuvant chemotherapy to CCRT increase the number of patients with adverse events compared with CCRT only</measure>
    <time_frame>18 months after the enrollment of the last patient</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Hypopharyngeal Cancer</condition>
  <arm_group>
    <arm_group_label>CCRT only arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>no neoadjuvant chemotherapy before definitive CCRT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>neoadjuvant chemotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 cycles of TPF chemotherapy before definitive CCRT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant docetaxel/cisplatin/fluorouracil</intervention_name>
    <description>2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.</description>
    <arm_group_label>neoadjuvant chemotherapy arm</arm_group_label>
    <other_name>Docetaxel (taxotere)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>No treatment before definitive CCRT</intervention_name>
    <description>concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43</description>
    <arm_group_label>CCRT only arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically/cytologically proven stage III/IVM0 hypopharyngeal or base of tongue
             cancer

          -  One or more evaluable or measurable lesion

          -  No prior chemotherapy, radiation, or surgery

          -  ECOG 0-2

        Exclusion Criteria:

          -  Distant metastasis

          -  Other malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Keunchil Park</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>neoadjuvant chemotherapy</keyword>
  <keyword>definitive chemoradiation therapy</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>base of tongue</keyword>
  <keyword>Locally advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

